Pharos: open-angle glaucoma (131 associated targets)

Disease Summary

Associated Targets (131)

Tbio

73

Tclin

32

Tchem

14

Tdark

12

Disease Ontology Description

A glaucoma characterized by optic nerve damage resulting in progressive loss of visual field and increased pressure in the eye due to trabecular blockage.

DataSource References

JensenLab Experiment TIGA: DOID:1067

DrugCentral Indication: DOID:1067

CTD: DOID:1067

eRAM: DOID:1067

GWAS Targets (108)

Items per page:

1 – 5 of 108

Target	TDL	Study Count	SNP Count	Beta Count	Odds Ratio	Evidence (Mean Rank Score)
Tumor suppressor ARF (CDKN2A)	Tbio	10	9	0	1.3	98.1

Tumor suppressor ARF (CDKN2A)	Tbio	10	9	0	1.3	98.1

Cyclin-dependent kinase inhibitor 2A (CDKN2A)	Tbio	10	9	0	1.3	98.1

Cyclin-dependent kinase inhibitor 2A (CDKN2A)	Tbio	10	9	0	1.3	98.1

Cyclin-dependent kinase 4 inhibitor B (CDKN2B)	Tbio	10	9	0	1.3	98.1

Items per page:

1 – 5 of 108

Target	TDL	Beta Count	Odds Ratio	Evidence (Mean Rank Score)
Tumor suppressor ARF (CDKN2A)	Tbio	0	1.3	98.1

Tumor suppressor ARF (CDKN2A)	Tbio	0	1.3	98.1

Cyclin-dependent kinase inhibitor 2A (CDKN2A)	Tbio	0	1.3	98.1

Cyclin-dependent kinase inhibitor 2A (CDKN2A)	Tbio	0	1.3	98.1

Cyclin-dependent kinase 4 inhibitor B (CDKN2B)	Tbio	0	1.3	98.1

Beta Count

Odds Ratio

Disease Hierarchy

Parents

glaucoma (195)

Tbio

117

Tclin

39

Tchem

21

Tdark

18

Children

primary open angle glaucoma (13)

Tbio

10

Tchem

2

Tclin

1

low tension glaucoma (5)

Tbio

4

Tchem

1

juvenile glaucoma (4)

Tchem

2

Tbio

2

residual stage of open angle glaucoma (0)

Target Novelty (Tin-x)